Replies to post #122413 on Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Perspective as we go unrecognized by the "wall"

[polarbear77]

Excellent perspective & analysis NWDR; thank you for your post.

And Xena and others have explained & highlighted the various MM & HFT methods of controlling the price action in this low volume & marginalized & relatively unknown Anavex security; NEVERTHELESS I'll admit it is head-scratching how we could still have a market cap of a company treating just 10% of the insomnia market.

Perhaps Froll's risky & tricky biotech warnings mean that us retail investors should simply:

• ignore the numerous positive signals and signs recently and the independent researchers' efficacy results from WSU for MS and MJFF's Dr Francardo for Parkinson's and
• ignore the words of Dr George Perry and
• ignore the words of Dr Andrew Cole and
• ignore the MTA interest of Biogen in our compound and
• ignore the fact that our CEO has illustrated the ULTIMATE sign of confidence with S-4 regulated insider purchases of stock and
• ignore the real world perspectives of our patients' caregivers from Australia trial (surely sugar pills induce similar responses) and
• ignore the improvement of 100% of insomnia sufferers and
• ignore the fact that our CEO continues to affirmatively assert that the compound crosses the blood brain barrier (as mild side effects only occurs near the highest 50mg dosage (excellent sign)) and
• ignore the upsloping 57 week cognition improvements on the MMSE and ADCS-ADL and P300 amplitude charts that the Company is STANDING BY TO THIS DAY and
• ignore the fact that the Company CONTINUES to represent their affirmative and unambiguous claims of "restores cellular homeostasis" and "provides dose dependent cognitive improvement" and
• ignore the fact that the mainstream media/biotech analysts and BP funded researchers are not interested in publicly discussing the Anavex MOA and its unique approach towards battling CNS diseases as they are, and will continue to be, reticent to admit that smallcap Anavex has the promise that they have failed to achieve (after billions & decades of failed tau protein removal efforts)


EOM. All must DYODD. I was at best a B student in science. This communication does not constitute a recommendation to buy or sell this or any other stock. Good night.

[Turner2017]

Nice calculations....when do you think Anavex will get its first FDA approval? Assuming the Rett trial goes well.

[attilathehunt]

Well done NWDR!

[Batermere]

Nicely done, NWDR. All of those could very well happen or maybe just one or two of them. One is all it would take to get to $80/share.

[Talon38]

NWDR....Like your analysis, both practical and spiritual reward. Don't we all appreciate having a stock in our portfolio that rewards us monetarily but. more importantly allows us to be a part of a company that will bring healing to millions of people from children to seniors.

[Stockdoggy]

Well said. This is my thinking. If you are going to invest in a risky biotech, you should try to find one where, if the company does succeed, the benefits and monetary gains will be substantial. Curing cancer through immunotherapy was once a good risk/reward but today the field is extremely crowded. Yes, Alzheimer's is a difficult nut to crack, but because of this there is a lack of available drugs to treat the disease and hence the bar for approval is low. Just the ability to treat insomnia for those who have the disease should garner approval for A2-73, and if that does not work out, at least AVXL is not a one trick pony. It appears likely to me that eventually this company will get a drug approved, even if there are some setbacks along the way. Patience required....

[McMagyar]

Restores Cellular Homeostasis!

Doesn't all disease start with
Cellular Imbalance?

[nidan7500]

NWDR...EXCELLENT, informative, rational post. I agree w/everything except for one thing. I believe the dynamics of the communications systems today and the scope(s) of A2-73 treatments along with changes in FDA (and other) regulatory bodies will serve to accelerate change in patient care. We may see concurrent/simultaneous treatment breakouts WW. If A2-73 is an effective treatment people WW will respond quickly on behalf of their patient/family member/other. No need for serial trials, IMO.

I believe the FDA's new mode (RWE) reasoning and the fact that A2-73 has no AE that we are aware of will quickly (read spontaneously) drive a demand process. And, speaking of positive, how about sharing such treatment knowledge WW? All CNS patients WW, regardless of country/politics get an opportunity for treatment are candidates. Yes, a bit of fantasy but not out of the question.

I am hopeful that Dr. M.'s thesis on restored CNS homeostasis restorative/regenerative capability is proven true and that will reduce clinical failure rates from those we have seen till now.

Bottom line, the whole time line for climbing out of the treatment hole we are in will be greatly accelerated.